Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings-Reference-Cited by-同舟云学术

Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings

Published:2018-08 Issue: Volume:1092 Page:515-523
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

El Mubarak Mohamed A.,Leontari Iliana,Efstathia Giannopoulou,Vrettos Eirinaios I.,Shaikh Abdul kadar,Konstantinos Siatis E.,Danika Charikleia,Kalofonos Haralabos P.,Tzakos Andreas G.,Sivolapenko Gregory B.

Funder

DEDEVAP

European Union

Greek State

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference27 articles.

1. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors;Adams;Clin. Ther.,2007

2. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma;Goodman;Clin. Cancer Res.,2007

3. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J. Clin.,2012

4. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors;Blumenthal;Oncologist,2012

5. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers;Kontovinis;BMC Cancer,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives;Pharmaceutics;2024-04-19

2. Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties;Pharmaceutics;2022-02-04

3. Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile;European Journal of Medicinal Chemistry;2019-03

4. Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients;Journal of Pharmaceutical and Biomedical Analysis;2019-02